The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Effect of Cyclosporine on Reperfusion Injury in Acute Myocardial Infarction
Abstract
BACKGROUND: Experimental evidence suggests that cyclosporine, which inhibits the opening of mitochondrial permeability-transition pores, attenuates lethal myocardial injury that occurs at the time of reperfusion. In this pilot trial, we sought to determine whether the administration of cyclosporine at the time of percutaneous coronary intervention (PCI) would limit the size of the infarct during acute myocardial infarction. METHODS: We randomly assigned 58 patients who presented with acute ST-elevation myocardial infarction to receive either an intravenous bolus of 2.5 mg of cyclosporine per kilogram of body weight (cyclosporine group) or normal saline (control group) immediately before undergoing PCI. Infarct size was assessed in all patients by measuring the release of creatine kinase and troponin I and in a subgroup of 27 patients by performing magnetic resonance imaging (MRI) on day 5 after infarction. RESULTS: The cyclosporine and control groups were similar with respect to ischemia time, the size of the area at risk, and the ejection fraction before PCI. The release of creatine kinase was significantly reduced in the cyclosporine group as compared with the control group (P=0.04). The release of troponin I was not significantly reduced (P=0.15). On day 5, the absolute mass of the area of hyperenhancement (i.e., infarcted tissue) on MRI was significantly reduced in the cyclosporine group as compared with the control group, with a median of 37 g (interquartile range, 21 to 51) versus 46 g (interquartile range, 20 to 65; P=0.04). No adverse effects of cyclosporine administration were detected. CONCLUSIONS: In our small, pilot trial, administration of cyclosporine at the time of reperfusion was associated with a smaller infarct by some measures than that seen with placebo. These data are preliminary and require confirmation in a larger clinical trial.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The mitochondrial permeability transition pore and its role in cell death
CROMPTON, M. (1999) · Biochemical Journal · doi:10.1042/bj3410233 · Cited by 2,432
Baines, C. P., Kaiser, R. A., Purcell, N. H., Blair, N. S., Osinska, H., Hambleton, M. A., Brunskill, E. W., Sayen, M. R., Gottlieb, R. A., Dorn, G. W., et al. (2005) · Nature · doi:10.1038/nature03434 · Cited by 2,280
The “no-reflow” phenomenon after temporary coronary occlusion in the dog
Kloner, R. A., Ganote, C. E., & Jennings, R. B. (1974) · Journal of Clinical Investigation · doi:10.1172/jci107898 · Cited by 1,842
Nakagawa, T., Shimizu, S., Watanabe, T., Yamaguchi, O., Otsu, K., Yamagata, H., Inohara, H., Kubo, T., & Tsujimoto, Y. (2005) · Nature · doi:10.1038/nature03317 · Cited by 1,635
Di Lisa, F., Menabò, R., Canton, M., Barile, M., & Bernardi, P. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m006825200 · Cited by 678
Cited by
Galluzzi, L., Vitale, I., Aaronson, S. A., Abrams, J. M., Adam, D., Agostinis, P., Alnemri, E. S., Altucci, L., Amelio, I., Andrews, D. W., et al. (2018) · Cell Death & Differentiation · doi:10.1038/s41418-017-0012-4 · Cited by 6,680
Myocardial ischemia-reperfusion injury: a neglected therapeutic target
Hausenloy, D. J., & Yellon, D. M. (2013) · Journal of Clinical Investigation · doi:10.1172/jci62874 · Cited by 2,357
Regulated necrosis: the expanding network of non-apoptotic cell death pathways
Berghe, T. V., Linkermann, A., Jouan-Lanhouet, S., Walczak, H., & Vandenabeele, P. (2014) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3737 · Cited by 1,735
Eldridge, S. M., Lancaster, G. A., Campbell, M. J., Thabane, L., Hopewell, S., Coleman, C. L., & Bond, C. M. (2016) · PLOS ONE · doi:10.1371/journal.pone.0150205 · Cited by 1,581
Linkermann, A., & Green, D. R. (2014) · New England Journal of Medicine · doi:10.1056/nejmra1310050 · Cited by 1,103
The machineries, regulation and cellular functions of mitochondrial calcium
Giorgi, C., Marchi, S., & Pinton, P. (2018) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-018-0052-8 · Cited by 941
Cyclosporine before PCI in Patients with Acute Myocardial Infarction
Cung, T.-T., Morel, O., Cayla, G., Rioufol, G., Garcia-Dorado, D., Angoulvant, D., Bonnefoy-Cudraz, E., Guérin, P., Elbaz, M., Delarche, N., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1505489 · Cited by 713
Self-citationMesenchymal stem cell exosome: a novel stem cell-based therapy for cardiovascular disease
Lai, R. C., Chen, T. S., & Lim, S. K. (2011) · Regenerative Medicine · doi:10.2217/rme.11.35 · Cited by 553
Luongo, T. S., Lambert, J. P., Yuan, A., Zhang, X., Gross, P., Song, J., Shanmughapriya, S., Gao, E., Jain, M., Houser, S. R., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.06.017 · Cited by 384
The role of the mitochondrial permeability transition pore in heart disease
Halestrap, A. P., & Pasdois, P. (2009) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/j.bbabio.2008.12.017 · Cited by 362
Cardiac Aging: From Molecular Mechanisms to Significance in Human Health and Disease
Dai, D.-F., Chen, T., Johnson, S. C., Szeto, H., & Rabinovitch, P. S. (2012) · Antioxidants & Redox Signaling · doi:10.1089/ars.2011.4179 · Cited by 334
Mitochondrial Permeability Transition: New Findings and Persisting Uncertainties
Izzo, V., Bravo-San Pedro, J. M., Sica, V., Kroemer, G., & Galluzzi, L. (2016) · Trends in Cell Biology · doi:10.1016/j.tcb.2016.04.006 · Cited by 205
Gibson, C. M., Giugliano, R. P., Kloner, R. A., Bode, C., Tendera, M., Jánosi, A., Merkely, B., Godlewski, J., Halaby, R., Korjian, S., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehv597 · Cited by 162
Mitochondrial DNA as an inflammatory mediator in cardiovascular diseases
Nakayama, H., & Otsu, K. (2018) · Biochemical Journal · doi:10.1042/bcj20170714 · Cited by 160
Porteous, C. M., Logan, A., Evans, C., Ledgerwood, E. C., Menon, D. K., Aigbirhio, F., Smith, R. A. J., & Murphy, M. P. (2010) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2010.06.001 · Cited by 121
Wang, Z., Liu, D., Varin, A., Nicolas, V, Courilleau, D., Mateo, P., Caubere, C., Rouet, P., Gomez, A.-M., Vandecasteele, G., et al. (2016) · Cell Death & Disease · doi:10.1038/cddis.2016.106 · Cited by 106
“Inhibition of MPT has thus become an attractive therapeutic strategy in cardioprotection.(15) Cyclic 3′,5′-adenosine monophosphate (cAMP) is a major”
BackgroundEndonuclease G mediates α‐synuclein cytotoxicity during Parkinson's disease
Büttner, S., Habernig, L., Broeskamp, F., Ruli, D., Vögtle, F. N., Vlachos, M., Macchi, F., Küttner, V., Carmona‐Gutierrez, D., Eisenberg, T., et al. (2013) · The EMBO Journal · doi:10.1038/emboj.2013.228 · Cited by 87
Nanoparticle-Mediated Drug Delivery System for Cardiovascular Disease
Matoba, T., & Egashira, K. (2014) · International Heart Journal · doi:10.1536/ihj.14-150 · Cited by 83
Carraro, M., Carrer, A., Urbani, A., & Bernardi, P. (2020) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2020.05.014 · Cited by 71
Nuclear-encoded mitochondrial proteins and their role in cardioprotection
Boengler, K., Heusch, G., & Schulz, R. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2011.01.009 · Cited by 68
Myocardial ‘no-reflow’ — diagnosis, pathophysiology and treatment.
Wong, D. T. L., Puri, R., Richardson, J. D., Worthley, M. I., & Worthley, S. G. (2013) · International Journal of Cardiology · doi:10.1016/j.ijcard.2012.12.049 · Cited by 66
Cardioprotective effects of mineralocorticoid receptor antagonists at reperfusion
Schmidt, K., Tissier, R., Ghaleh, B., Drogies, T., Felix, S. B., & Krieg, T. (2010) · European Heart Journal · doi:10.1093/eurheartj/ehp555 · Cited by 52
Liu, C., Yang, F., Cheng, S., Liu, Y., Wan, L., & Cong, H. (2017) · Cardiovascular Therapeutics · doi:10.1111/1755-5922.12225 · Cited by 52
Stamerra, C. A., Di Giosia, P., Giorgini, P., Ferri, C., Sukhorukov, V. N., & Sahebkar, A. (2022) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2022/9530007 · Cited by 48
RetractedTherapeutic Peptides to Treat Myocardial Ischemia-Reperfusion Injury
Fernandez Rico, C., Konate, K., Josse, E., Nargeot, J., Barrère-Lemaire, S., & Boisguérin, P. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.792885 · Cited by 45
Linkermann, A., Konstantinidis, K., & Kitsis, R. N. (2016) · Cell Death & Differentiation · doi:10.1038/cdd.2015.151 · Cited by 36
Metadata
- Authors
- Piot, C., Croisille, P., Staat, P., Thibault, H., Rioufol, G., Mewton, N., Elbelghiti, R., Cung, T. T., Bonnefoy, E., Angoulvant, D., Macia, C., Raczka, F., Sportouch, C., Gahide, G., Finet, G., André-Fouët, X., Revel, D., Kirkorian, G., Monassier, J.-P., Derumeaux, G., & Ovize, M.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2008-07-31
- Volume
- 359
- Issue
- 5
- Pages
- 473-481
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2153298328
- Cited by
- 1,339
- References
- 5
- FWCI
- 69.94
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.